| Chelsea Donahue, AUD | |
|
600 Ridgely Ave Ste 110, Annapolis, MD 21401-1082 | |
| (410) 647-7795 | |
| (410) 315-8823 |
| Full Name | Chelsea Donahue |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 3 Years |
| Location | 600 Ridgely Ave Ste 110, Annapolis, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235801291 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 01571 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chesapeake Hearing Centers Inc | 0840243259 | 7 |
News Archive
The U.S. Food and Drug Administration today approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population.
A clinical trial treating the papillomaviruses responsible for genital warts was on target at the halfway mark, according to Australian of the Year 2006 Professor Ian Frazer and trial manager, sexual health specialist Dr David Jardine
When thousands of experimental biology researchers gather in Boston this weekend, many of them undoubtedly will be presenting work related to the hunt for the next generation of antibiotics and how to battle back existing and emerging superbugs.
› Verified 6 days ago
| Provider Name | Chesapeake Hearing Centers Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093850216 PECOS PAC ID: 0840243259 Enrollment ID: O20050225000294 |
News Archive
The U.S. Food and Drug Administration today approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population.
A clinical trial treating the papillomaviruses responsible for genital warts was on target at the halfway mark, according to Australian of the Year 2006 Professor Ian Frazer and trial manager, sexual health specialist Dr David Jardine
When thousands of experimental biology researchers gather in Boston this weekend, many of them undoubtedly will be presenting work related to the hunt for the next generation of antibiotics and how to battle back existing and emerging superbugs.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chelsea Donahue, AUD 650 Ritchie Hwy Ste 104, Severna Park, MD 21146-3910 Ph: (410) 647-7795 | Chelsea Donahue, AUD 600 Ridgely Ave Ste 110, Annapolis, MD 21401-1082 Ph: (410) 647-7795 |
News Archive
The U.S. Food and Drug Administration today approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
A study involving 678 individuals who apply pesticides, culled from a U.S. Agricultural Health Study of over 50,000 farmers, recently found that exposure to certain pesticides doubles one's risk of developing an abnormal blood condition called MGUS (monoclonal gammopathy of undetermined significance) compared with individuals in the general population.
A clinical trial treating the papillomaviruses responsible for genital warts was on target at the halfway mark, according to Australian of the Year 2006 Professor Ian Frazer and trial manager, sexual health specialist Dr David Jardine
When thousands of experimental biology researchers gather in Boston this weekend, many of them undoubtedly will be presenting work related to the hunt for the next generation of antibiotics and how to battle back existing and emerging superbugs.
› Verified 6 days ago
Dr. Brittany Bailey Tuscany, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 230, Annapolis, MD 21401 Phone: 410-266-3900 | |
Samantha Johanna Mcmahon, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2002 Medical Pkwy Ste 230, Annapolis, MD 21401 Phone: 410-266-3900 Fax: 410-266-9245 | |
Carrie Veneman Davis, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 2002 Medical Pkwy, Suite 230, Annapolis, MD 21401 Phone: 410-266-3900 | |
Julia Elizabeth Fitzer, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 2530 Riva Rd, Ste 309, Annapolis, MD 21401 Phone: 410-266-7540 | |
Dr. Megan Espinosa, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1125 West St Ste 601, Annapolis, MD 21401 Phone: 443-716-5016 | |
Dr. Danielle Mills, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 2525 Riva Rd Ste 102, Annapolis, MD 21401 Phone: 410-671-5656 Fax: 443-272-4990 |